A Phase 2 interventional study of caspofungin acetate and Comparator: AmBisome in Neutropenia and Fever, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2017-02-23.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment
This study is a double-blind, randomized study of MK0991 versus liposomal amphotericin B in the empirical treatment of pediatric patients (ages 2 through 17 years) who have an absolute neutrophil count (ANC) below 500/microliter and who have fever despite broad antibiotic coverage. Such patients would be candidates for empirical therapy with an intravenous anti-fungal agent.
405 studies on the registry are indexed under Neutropenia; 60 are open to participants now.
This study's enrollment of 100 is close to the median of 93 across 285 interventional studies indexed under Neutropenia.
Browse Neutropenia studies →Merck Sharp & Dohme LLC is the lead sponsor of 2,159 studies on the registry; 133 are open to participants now.
Of its 497 completed or terminated interventional studies of FDA-regulated products, 369 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:
Duration of Treatment: 28-90 days
Also known as: MK0991
Duration of Treatment: 28-90 days
To estimate the proportion of patients treated with caspofungin reporting one or more clinical and/or laboratory drug-related adverse experience(s) during the study drug therapy period plus 14 days posttherapy
Proportion of patients with a favorable overall response
No study locations are listed for this record.
This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Caspofungin